Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott's Piramal Acquisition Is $3.72 Billion Push In Emerging Markets With Established Products

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Abbott is all set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare, ending months of speculation on which multinational would secure India's fourth-largest pharma compan

You may also be interested in...



Deal Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?

Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales.

From Pharma To Telecom To Data Analytics, Piramal Surprises Again - To Buy Decision Resources For $635 Mln

India’s takeover tycoon looks at information arbitrage.

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)

[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel